Tag Archives: Fabre

Aventis v. Hospira – How to Meet the Therasense Standards

On April 9, 2012, The Fed. Cir. affirmed a holding by the district court that rendered two (then) Sanofi add-on patents on infusion vehicles for docetaxel unenforceable due to inequitable conduct. The inventors, particularly inventor/project manager¬†Fabre, were found to have … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , | 2 Comments